Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials. - Wikidata - wikimedia - TriplyDB

Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.

Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.

http://www.wikidata.org/entity/Q38921198

about

Review of targeted treatments in fragile X syndrome The NIH Toolbox Cognitive Battery for intellectual disabilities: three preliminary studies and future directions Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study.β-Arrestin2 Couples Metabotropic Glutamate Receptor 5 to Neuronal Protein Synthesis and Is a Potential Target to Treat Fragile X.Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders.Delta rhythmicity is a reliable EEG biomarker in Angelman syndrome: a parallel mouse and human analysis.Fragile X Syndrome: Prevalence, Treatment, and Prevention in China Arbaclofen in fragile X syndrome: results of phase 3 trials Updated report on tools to measure outcomes of clinical trials in fragile X syndrome.Fragile X targeted pharmacotherapy: lessons learned and future directions.Effects of a social stimulus on gene expression in a mouse model of fragile X syndrome Fragile X Syndrome: Lessons Learned from the Most Translated Neurodevelopmental Disorder in Clinical Trials.Metabotropic glutamate receptor 5 responses dictate differentiation of neural progenitors to NMDA-responsive cells in fragile X syndrome.Characterization, treatment patterns, and patient-related outcomes of patients with Fragile X syndrome in Germany: final results of the observational EXPLAIN-FXS study.Finding novel distinctions between the sAPPα-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissue Current Perspectives in Autism Spectrum Disorder: From Genes to Therapy.Defining Precision Medicine Approaches to Autism Spectrum Disorders: Concepts and Challenges Neurobiologically-based treatments in Rett syndrome: opportunities and challenges.Commentary: Depletion of the Fragile X Mental Retardation Protein in Embryonic Stem Cells Alters the Kinetics of Neurogenesis.Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research.Clinical trials for neurodevelopmental disorders: At a therapeutic frontier.Genetic Approaches to Understanding Psychiatric Disease.Opportunities and challenges in modeling human brain disorders in transgenic primates.The selective metabotropic glutamate receptor 5 antagonist mavoglurant (AFQ056) reduces the incidence of reflux episodes in dogs and patients with moderate to severe gastroesophageal reflux disease.Human pluripotent stem cells in modeling human disorders: the case of fragile X syndrome.mGlu5 negative allosteric modulators: a patent review (2013 - 2016).A brain proteomic investigation of rapamycin effects in the Tsc1+/- mouse model.A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome.Translation in fragile X: no home runs in the first at-bat.Genetic rodent models of brain disorders: Perspectives on experimental approaches and therapeutic strategies.Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology.The Search for an Effective Therapy to Treat Fragile X Syndrome: Dream or Reality?Combination Therapy in Fragile X Syndrome; Possibilities and Pitfalls Illustrated by Targeting the mGluR5 and GABA Pathway Simultaneously.Fragile X syndrome and fragile X-associated disorders.Metformin ameliorates core deficits in a mouse model of fragile X syndrome.Drugs for rare disorders.Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.Roles for Arc in metabotropic glutamate receptor-dependent LTD and synapse elimination: Implications in health and disease.Developmental timing and critical windows for the treatment of psychiatric disorders.

P2860

Q28077180-FD9BE93D-8375-41FC-9887-47582399E80B Q29109561-4A46E3D0-8A55-4079-96DB-3D1CB08985F9 Q31043571-2EBAF20D-F47F-49A1-B854-D41857128AF7 Q33562835-EB9414FC-68CC-4A3C-970C-6D2DFC7D9424 Q33635517-0651B4A9-131A-4395-86D9-43950F0A54EB Q33651529-6D9D8262-1D9E-4644-876C-B4FF40D39EAB Q33766106-78B1B388-6481-4E6E-A38C-8F92DE378E4E Q33785963-ACE32073-B481-4343-9843-C2EEEA25DBE7 Q33785978-017C32E8-B5E9-4442-A14C-96ED0C8D3B57 Q33785983-C8273453-7C3D-485B-ABAD-C2F19683F6C8 Q33827442-59D42D09-1ECF-40E6-AC1B-5676B6BFE9FE Q34555109-CCDEA1FC-4D53-48B2-80FA-BB53317DA314 Q36076206-B5D967B9-80B8-49FF-ACA1-000970835EF4 Q36128713-DDF05B63-3A1B-4638-BD97-5533BC3EDC9C Q36925690-415CAEE7-C15B-41A8-BA77-16EBF90041C1 Q37444926-A91BE04E-15EF-4761-915E-8CA6530991A8 Q37447215-86F1F9C9-6CBF-4506-A4CD-22EF4A2ACE3A Q37558440-A2F55E7E-4AD1-466F-9D57-C97BAC8129EA Q37627065-701EFAE8-42BF-46CB-8A01-529D563156D9 Q38620643-A6F6480B-32EE-4480-992F-DB56E69EC888 Q38669576-9B3428AD-0A2C-45D9-8DCC-1301E4B7C407 Q38695866-83B04074-AC71-4AA7-BCD3-B05032CA6324 Q38728415-0B56E93A-14C5-4A65-88ED-B272A6C554B0 Q38826903-BE14B6D1-1DAC-4A8D-9EBB-F2E36814B232 Q38880408-3CB10018-B88F-4D36-BC5C-A3A578B4CB4E Q39024323-5BD19AC0-83DE-4115-BF50-01C3E31170F3 Q39076410-C0E30074-CCDA-4215-A8CB-EBCA5BCBB00B Q41211684-562AA45E-1FC4-43A6-9993-40DD022A7895 Q41215871-5FFD3B3E-BAF8-45B1-B8F3-346E950B6298 Q42340005-521DF999-E7FC-4B4B-8AA8-02BE493124D2 Q46075544-506B2949-B024-4A87-8159-512ADE83C608 Q46111793-77FABCCC-F29C-4EDC-826B-15CB77444A17 Q47110293-FEFFFF63-F81B-48A4-BC90-EE4F4B9B10AE Q47112165-FB947DE0-2E55-4F62-982D-6D9A61A19B10 Q47140616-3D5F4C11-0710-4B3D-BEF9-EF27BE2A3F7A Q47296688-4B37A60B-F6AE-4AB9-A784-B14E2FCB14C3 Q47334709-4138F7BD-B0B2-4B4D-80F5-C5AF437E670A Q47729702-A06DCE21-533E-401F-A341-7B4B546079E5 Q47752204-700F1411-E5E0-47C5-9773-4F8519B00865 Q47895125-061AF13C-9232-4F3F-B9BC-A366070C3A3E

P2860

Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.

http://www.wikidata.org/entity/Q38921198

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Mavoglurant in fragile X syndr ...... nd, placebo-controlled trials.

@en

type

label

Mavoglurant in fragile X syndr ...... nd, placebo-controlled trials.

@en

prefLabel

Mavoglurant in fragile X syndr ...... nd, placebo-controlled trials.

@en

P1433

Q38921198-935A6234-6FEC-4A4C-BB9A-00AB9C5B700C

P1476

Q38921198-7AE8B8BA-A74B-4036-9145-0EC6042E2DD9

P2093

Q38921198-193C7342-A454-4DD4-84C4-7D1E41F4BBA6

Q38921198-21C029B0-FDDD-451B-A793-0FFA0AC2B6A6

Q38921198-2DC00F5C-7D45-48C3-8782-F64A14ADD3D4

Q38921198-3F3FEF51-1318-4C24-A8CD-8FAE863B74A6

Q38921198-50B22120-8A0B-4C39-9723-E3A11D500836

Q38921198-6AC017DF-8C0A-4DCC-B738-3B57600B031D

Q38921198-7DF2DB9D-0AF6-477B-8E28-6089891E007D

Q38921198-9CEA0ECC-C100-4680-8692-24D1E3D73976

Q38921198-BDFE4EED-0631-4C23-ABCC-5FA8C91B63E6

Q38921198-C365AB28-C699-4AB1-BA61-0F1E6ED50D11

P2860

Q38921198-01E4C452-CB81-4A6C-83F0-5BC14914EA71

Q38921198-0433ABDF-AE0B-41D6-825D-66E44B61AFCD

Q38921198-141167AD-D9C6-4426-92CF-062BC11C18CD

Q38921198-2A8BE495-BD33-440F-89B9-66BBEFDB42EA

Q38921198-30B6766A-B64D-4D7E-B7CB-2C7C097C1DD9

Q38921198-590023C8-7A9E-4D2D-ACCC-1964549BD72B

Q38921198-69CF9198-3B11-4BE4-8782-5449EDF5D3C3

Q38921198-7B1E4C3E-91AD-43CB-8822-593B7ED96E63

Q38921198-7B2614EE-37BB-4BB6-8B40-3AAE0DCAC089

Q38921198-7D5B71A2-C821-4B9A-A7F0-FD611E2651F0

P304

Q38921198-19855BC8-5C57-404D-8CB3-2E54D1AD42E5

P31

Q38921198-CD02E40E-B81B-43D2-9F8B-63C439F4A357

P356

Q38921198-C6A903D5-90BE-4D19-AD48-7D110243387A

P407

Q38921198-1E82CF9A-E105-4B23-89C7-7EFDB6752559

P433

Q38921198-F0E48502-BFCA-4C70-9A88-0A04A9BC5DD1

P478

Q38921198-76647583-EF58-4A0C-9A10-CA39D4F1D993

P577

Q38921198-BF069A3A-2525-42DF-83C5-A06FE993FDE8

P5875

Q38921198-A00B781C-00E7-4C58-8D0D-10875060B6D4

P698

Q38921198-D7391AD5-886D-4955-BD0B-FB8AF728D038

P921

Q38921198-6039995F-B8C8-469C-A85F-4DF372924121

P356

SCITRANSLMED.AAB4109

P1433

Science Translational Medicine

P1476

Mavoglurant in fragile X syndr ...... nd, placebo-controlled trials.

@en

P2093

Barbara Koumaras

http://www.w3.org/2001/XMLSchema#string

Elizabeth Berry-Kravis

http://www.w3.org/2001/XMLSchema#string

Florian von Raison

http://www.w3.org/2001/XMLSchema#string

George Apostol

http://www.w3.org/2001/XMLSchema#string

Gottfried Maria Barth

http://www.w3.org/2001/XMLSchema#string

Jeannie Visootsak

http://www.w3.org/2001/XMLSchema#string

Karin Rerat

http://www.w3.org/2001/XMLSchema#string

Liansheng Zhu

http://www.w3.org/2001/XMLSchema#string

Marc Brinkman

http://www.w3.org/2001/XMLSchema#string

Perrine Charles

http://www.w3.org/2001/XMLSchema#string

P2860

The Repetitive Behavior Scale-Revised: Independent Validation in Individuals with Autism Spectrum Disorders

Altered synaptic plasticity in a mouse model of fragile X mental retardation

The FMRP regulon: from targets to disease convergence

The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses

Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome

The mGluR theory of fragile X mental retardation

Electrocortical changes associated with minocycline treatment in fragile X syndrome.

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.

AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome.

Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes.

P304

321ra5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.AAB4109

http://www.w3.org/2001/XMLSchema#string

P407

P433

321

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

290475580

http://www.w3.org/2001/XMLSchema#string

P698

26764156

http://www.w3.org/2001/XMLSchema#string

P921